Abbott India Q3 Results Date updates, Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. It was established in 1944.
The company is a part of Abbott Laboratories. The group has a presence in 160+ countries across the globe with a legacy of 130+ years.
The product portfolio of over 125 products across various therapeutic areas such as women’s health, gastroenterology, central nervous system (CNS), metabolics, multi-specialty (Pain management, insomnia, nutritional supplements, and vitamins), vaccines, consumer health, etc. In FY22, Co. introduced 10 new products in different therapeutic areas.
Top 15 brands are leaders (positioned at #1 or #2) in their respective segments and contribute to over 80% of the Company’s core business.
OTC (Over-the-Counter) is a strategic focus area for the co. to improve access and affordability of everyday health products to our patients.
Further, their focus will continue to remain in antacids and laxatives while establishing presence in analgesics and preventive health. Co. also has Increased focus on alternate channels – such as modern trade pharmacy chains, and e-pharmacies.
Abbott india Q3 Results Date
In letter to exchanges “Abbott India inform you that a Meeting of the Board of Directors of the Company is scheduled to be held on Friday, February 10, 2023, interalia, to consider and approve the text of Unaudited Financial Results of the Company for the third quarter ended on December 31, 2022”.
Brokerage Call on Abbott India
Abbott has expanded its key portfolios and introduced 10 new products in FY22, in therapeutic areas of Women’s Health, Gastroenterology, Central Nervous System, Multi-speciality and Vaccines.
Having strong set of brands, with highest MR productivity among its domestic peers, and its ability to grow ahead of the market, backed by price increases and traction in new launches.
Cash on books also may be utilized for M&A in consumer health and vaccine brands. The brokerage maintains BUY with a target price of Rs23,100 at 40x on Sep’24 EPS. The stock currently trades at 44x and 38x on EPS of Rs451 and 519.6 of FY23/24E respectively.
CLSA maintains ‘buy’ on the shares of Abbott india with a revised target price of Rs 22,510. The brokerage sees a 16 percent earnings CAGR over FY 22-25
Also Read :- KPIT Tech Q3 Results Date, Will KPIT announce Dividend ?